Actively Recruiting
Randomized Study Comparing Izalontamab Brengitecan and Platinum-Pemetrexed Chemotherapy for EGFR-Mutated Non-Small Cell Lung Cancer After EGFR TKI Therapy Failure
Led by Bristol-Myers Squibb · Updated on 2026-10-09
500
Participants Needed
187
Research Sites
100 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating Izalontamab Brengitecan BMS-986507 compared with platinum-based chemotherapy combined with pemetrexed for patients with EGFR-mutated non-small cell lung cancer that has progressed despite prior EGFR tyrosine kinase inhibitor TKI therapy. This study is a randomized, open-label phase 23 trial sponsored by Bristol-Myers Squibb, aiming to determine effective treatment options after failure of EGFR TKI therapy. Participants receive one of several regimens including Izalontamab Brengitecan or platinum-based chemotherapy with pemetrexed, using drugs such as carboplatin, cisplatin, and pemetrexed administered at specified doses on specified days. The study uses a parallel design with randomized assignment to different treatment arms to compare outcomes. Throughout the study, participants will be monitored for progression-free survival and response to treatment using RECIST v1.1 criteria through blinded independent central review, with assessments continuing for up to three years. The recommended phase 3 dose of Izalontamab Brengitecan will be determined about three months after the first dose. Overall survival and multiple secondary outcomes will also be tracked, with the study lasting until November 2030.
CONDITIONS
Brief Title
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Research Team
B
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
F
First line of the email MUST contain NCT # and Site #.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here